Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03754920
Other study ID # ShanghaiUTCMjialijun
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date September 9, 2018
Est. completion date September 9, 2019

Study information

Verified date October 2018
Source Shanghai University of Traditional Chinese Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To determine the feasibility, safety and efficacy of fasting, participants are recruited in a 5-days fasting ( without any food, except unlimited mineral water),and do some fitness regimen (such as meditation and mild physical exercise ) during fasting.The samples will be collected from participates and subjected to comprehensive analysis ,including routine medical examination in blood, metabonomics and proteomics anlysis in serum and urine samples, gut microbiome analysis in stood samples, and so on.


Description:

1. Recruiting: 45 healthy people will be included in the clinical trial according to the Inclusion criteria and exclusion criteria.

2. Fasting : Participants fast for five days, without any food, except unlimited mineral water. Participants will do some fitness regimen (such as meditation and mild physical exercise ) during fasting.

3. Re-feeding: Gradually distribute participants with rice flour, porridge and juice in the next 3 days.

4. Follow-up :The health checklist is similar with that during fasting on the first month.

5. Data processing, statistics and analysis. Diet monitoring: The intake of glucose decreases, while the burning of fat increases, which can down-regulate glucose level in blood, up-regulate ketone level in urine. Thus, the fasting situation of participants can be monitored by the variation of blood glucose and urine ketone.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 45
Est. completion date September 9, 2019
Est. primary completion date April 9, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion criteria

1. 18-65 years old, no nationality limitation, no gender limitation;

2. Male weight = 50 kg, female weight = 45 kg;BMI: 19-28 kg/m²;

3. The index of physical examination is in line with health standards;

4. People who have gone through a 7-day fasting before ;

5. Agree to take part in the trials and sign the informed consent form.

Exclusion criteria

1. People with unhealthy habits, such as smoking(5 cigarettes per day, or can not stop smoking in the trial), excessive drinking(drink regularly in the recent 6 months or more than 14 units of alcohol per week (1 unit = 360 ml beer or 45 ml alcohol with 40% spirits or 150 ml wine)) ;

2. People who processed fasting within one month;

3. Pregnancy, current breast-feeding or menstrual period;

4. People who are marantic, malnourished or anorectic;

5. People who have cardiovascular disease(coronary heart disease, atherosclerosis, arrhythmia, etc), serious metabolic and psychiatric disorders(hypertension, type 2 diabetes, hyperthyroidism, etc.);

6. People who have Mental illness, cancer, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV), syphilis, human immunodeficiency virus (HIV) antibody positive.

7. people who has mental disorders according to the scales(Hamilton Anxiety Scale?Self-Rating Anxiety Scale?Self-rating depression scale)

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
prolonged fasting
Fasting for 5 days: Fasting with some fitness regimen, such as meditation and mild physical exercise; Feeding for 3 days: Gradually distribute participants with rice flour, porridge and juice.

Locations

Country Name City State
China Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Shanghai University of Traditional Chinese Medicine

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Weight Changes in weight will be assessed. Day 0, day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8; 1 month and 3 months post fasting
Primary Blood glucose Changes in blood glucose will be assessed. Day 0, day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8; 1 month and 3 months post fasting
Primary Insulin Changes in insulin will be assessed. Day 0, day 3, day 5, day 8; 1 month and 3 months post fasting
Primary Blood pressure Changes in blood pressure will be assessed. Day 0, day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8; 1 month and 3 months post fasting
Primary Waistline Changes in waistline will be assessed . Day 0, day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8; 1 month and 3 months post fasting
Primary IGF-1 Changes in IGF-1 will be assessed. Day 0, day 3, day 5, day 8; 1 month and 3 months post fasting
Primary Pulse Rate Changes in pulse rate will be assessed. Day 0, day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8; 1 month and 3 months post fasting
Primary Blood lipid test Changes in blood including HDL, LDL, TG, CHO and ect. will be assessed. Day 0, day 3, day 5, day 8; 1 month and 3 months post fasting
Primary Urine test Changes in urine including uric acid and ect. will be assessed. Day 0, day 3, day 5, day 8; 1 month and 3 months post fasting
Primary Liver and renal function test Changes in liver and renal function including AST,ALT,ALP, TP,ALB, Urea, Crea and ect will be assessed at 7:30 am. Day 0, day 3, day 5, day 8; 1 month and 3 months post fasting
Primary Serum metabolomics analysis Serum samples were collected and serum metabolomics (carbohydrate, lipid, amino acid and ect.) were sequenced and analyzed by High-throughput sequencing. Day 0, day 3, day 5, day 8; 1 month and 3 months post fasting
Secondary Urinary ketone Changes in urinary ketone will be assessed. Day 0, day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8; 1 month and 3 months post fasting
Secondary Vitamin examination Changes in vitamin including vitamin C,D,E and etc. will be assessed. Day 0, day 3, day 5, day 8; 1 month and 3 months post fasting
Secondary Thyroid function Changes in Thyroid function test including FT3,FT4,TSH will be assessed. Day 0, day 3, day 5, day 8; 1 month and 3 months post fasting
Secondary Inflammatory factors Changes in inflammatory factors includingIL1, IL2, IL6, IL10,TNF ,TGFß and etc. will be assessed. Day 0, day 3, day 5, day 8; 1 month and 3 months post fasting
Secondary Gut microbiome Stool samples were collected in time if possible and analyzed the composition /function of the intestinal microflora by High-throughput sequencing Day 0, day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8; 1 month and 3 months post fasting
Secondary Self-rating depression scale; The Scale ,includes half of items ues positive words and half is negatively,which could assess symptoms of depression. Item responses are ranked from 1 to 4, and higher scores correspond to more frequent symptoms. For each item,patients give a score according to whether the item has occurred: 1 = never/very rarely; 2 = once in a while/some of the time/occasionally; 3 = relatively often/very often/often; 4 = most of the time/always. Each items points accumulated as raw scores,the lowest raw score is 20 points, the highest raw score is 80 points. The raw scores multiply by 1.25, taking the integer part as the standard scores.The scale standard scores were used to define four categories of depression severity: within normal range or no significant psychopathology (below 51points); presence of minimal to mild depression (51-60points); presence of moderate to marked depression (61-70points). Day 0, day 3, day 5, day 8; 1 month and 3 months post fasting
Secondary Self-Rating Anxiety Scale; The Scale contains 20 questions. Each question is scored on a scale of 1-4 (never, some of the time, relatively often, most of the time). There are fifteen questions involved in the assessment could indicate the increase of anxiety levels, and rest of the questions assessment would decrease of the anxiety levels.Each items points accumulated as raw scores,the lowest raw score is 20 points, the highest raw score is 80 points. The raw scores multiply by 1.25, taking the integer part as the standard scores.The scale standard scores were used to define four categories of anxiety severity: within normal ranger no significant psychopathology (25-49points); presence of mild to moderate anxiety levels (50-59points); severe anxiety levels (60-69points); and presence of extreme depression (70-100points). Day 0, day 3, day 5, day 8; 1 month and 3 months post fasting
Secondary Hamilton Anxiety Scale Symptoms of generalized anxiety disorder as measured by the Hamilton Anxiety Scale (HAM-A) at 1 day?4 day?6 day?9 day?40 day. Each item is scored on a scale from 0 (not present) to 4 (severe) with a total score range of 0-56. Changes in HAM-A scores are calculated as the difference between the baseline HAM-A scores and scores at 1 day?4 day?6 day?9 day?40 day. Day 0, day 3, day 5, day 8; 1 month and 3 months post fasting
Secondary Hamilton Depression Scale Remission according to HAM-D: HAM-D17 score less than or equal to (=<) 7 or a HAM-D7 score =< 3. HAM-D17: standardized, clinician-administered rating scale; assesses 17 items characteristically associated with major depression. Individual items are scored on either a 3 point (0 to 2) or a 5 point scale (0 to 4), with 0=none/absent and 4=most severe. Total score: 0 to 66; higher score indicates more depression. HAM-D7: subset of HAM-D17; assesses 7 items associated with major depression. Total score: 0 to 26; higher score indicates more depression. Day 0, day 3, day 5, day 8; 1 month and 3 months post fasting
See also
  Status Clinical Trial Phase
Completed NCT05272332 - Gastric Ultrasound Prior to Extubation
Completed NCT04247464 - Short-term Fasting as an Enhancer of Chemotherapy: Pilot Clinical Study on Colorectal Carcinoma Patients N/A
Completed NCT01067001 - Minocycline HCl Extended Release Tablets 135 mg Oral Bioequivalence Study N/A
Completed NCT00757094 - Safety and Feasibility of Fasting While Receiving Chemotherapy N/A
Completed NCT01506713 - Bioequivalence Study of Clopidogrel Tablets 75 mg of Dr. Reddy's Under Fasting Conditions Phase 1
Completed NCT04514380 - Effect of Drinking Carbohydrate-containing Fluids on Gastric Residual Volume in Elderly Patients
Completed NCT05756868 - The Effect of Time-Restricted Feeding on Anthropometry, Biochemical Parameters, Diet Quality and Eating Behavior N/A
Completed NCT05134207 - The Effect of Oral Carbohydrate Solution on Anxiety and Comfort in Patients Undergoing Hip Arthroplasty N/A
Completed NCT05031598 - Long-term Fasting: Multi-system Adaptations in Humans N/A
Recruiting NCT04501393 - Recommended Clear Fluid Intake Volume at 2 Hours Prior to Esophagogastroduodenoscopy for Adult Patients N/A
Enrolling by invitation NCT04027478 - Can Fasting Decrease the Side Effects of Chemotherapy? N/A
Completed NCT05219136 - Improve the Comfort, Safety and Quality of Upper Endoscopy by a Modified Fasting Protocol N/A
Recruiting NCT04625608 - Effect of Premedicant Oral Paracetamol on Gastric Volume and pH Phase 4
Not yet recruiting NCT02562638 - Pre-Procedural Fasting in Cardiac Intervention N/A
Completed NCT01954836 - Short-Term Fasting During Chemotherapy in Patients With Gynecological Cancer- a Randomized Controlled Cross-over Trial N/A
Completed NCT01949987 - Does Oral Intake Decreases Postoperative Pain Score in Children N/A
Completed NCT01721187 - Satiety Effects on the Neural Valuation of Food N/A
Completed NCT01746719 - Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fasting Condition Phase 1
Completed NCT01713647 - Bioequivalence Study of Amlodipine / Losartan/ Hydrochlorothiazide of PHARMALINE, Lebanon Under Fastion Conditions Phase 1
Completed NCT01831700 - Bioequivalence Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg Under Fasting Conditions Phase 1